Genmab Lifts FY26 Earnings Guidance

MT Newswires · 2d ago
12:01 PM EDT, 08/06/2026 (MT Newswires) -- Genmab (GMAB.CO) raised its earnings guidance for 2026, thanks to higher total royalty revenue from multiple myeloma drug Darzalex and net sales of diffuse large B-cell lymphoma treatment Epkinly. The Danish biotechnology company now expects revenue of between $4.33 billion and $4.53 billion, up from its previous forecast of between $4.07 billion and $4.4 billion, according to a Thursday release. Genmab also anticipates gross profit in the range of $4.02 billion to $4.2 billion, up from $3.81 billion to $4.11 billion. Adjusted operating profit is expected to be between $1.07 billion and $1.39 billion, compared with the prior range of $900 million to $1.4 billion.